Details

Autor(en) / Beteiligte

• Altamura, Claudia
• Ornello, R.
• Ahmed, F.
• Negro, A.
• Miscio, A. M.
• Santoro, A.
• Alpuente, A.
• Russo, A.
• Silvestro, M.
• Cevoli, S.
• Brunelli, N.
• Grazzi, L.
• Baraldi, C.
• Guerzoni, S.
• Andreou, A. P.
• Lambru, G.
• Frattale, I.
• Kamm, K.
• Ruscheweyh, R.
• Russo, M.
• Torelli, P.
• Filatova, E.
• Latysheva, N.
• Gryglas-Dworak, A.
• Straburzynski, M.
• Butera, C.
• Colombo, B.
• Filippi, M.
• Pozo-Rosich, P.
• Martelletti, P.
• Sacco, S.
• Vernieri, F.

Titel

OnabotulinumtoxinA in elderly patients with chronic migraine: insights from a real-life European multicenter study

Ist Teil von

• Journal of neurology, 2023-02, Vol.270 (2), p.986-994

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2023

Quelle

MEDLINE

Beschreibungen/Notizen

• Introduction Although migraine prevalence decreases with aging, some older patients still suffer from chronic migraine (CM). This study aimed to investigate the outcome of OnabotulinumtoxinA (OBT-A) as preventative therapy in elderly CM patients. Methods This is a post hoc analysis of real-life prospectively collected data at 16 European headache centers on CM patients treated with OBT-A over the first three treatment cycles (i.e., Cy1-3). We defined: OLD patients aged ≥ 65 years and nonOLD those < 65-year-old. The primary endpoint was the changes in monthly headache days (MHDs) from baseline to Cy 1–3 in OLD compared with nonOLD participants. The secondary endpoints were the responder rate (RR) ≥ 50%, conversion to episodic migraine (EM) and the changes in days with acute medication use (DAMs). Results In a cohort of 2831 CM patients, 235 were OLD (8.3%, 73.2% females, 69.6 years SD 4.7). MHDs decreased from baseline (24.8 SD 6.2) to Cy-1 (17.5 SD 9.1, p  < 0.000001), from Cy-1 to Cy-2 (14.8 SD 9.2, p  < 0.0001), and from Cy-2 to Cy-3 (11.9 SD 7.9, p  = 0.001). DAMs progressively reduced from baseline (19.2 SD 9.8) to Cy-1 (11.9 SD 8.8, p  < 0.00001), to Cy-2 (10.9 SD 8.6, p  = 0.012), to Cy-3 (9.6 SD 7.4, p  = 0.049). The 50%RR increased from 30.7% (Cy-1) to 34.5% (Cy-2), to 38.7% (Cy-3). The above outcome measures did not differ in OLD compared with nonOLD patients. Conclusion In a population of elderly CM patients with a long history of migraine OBT-A provided a significant benefit, over the first three treatment cycles, as good as in non-old patients.